Reversible Z-E isomerism and pharmaceutical implications for SU5416

Area of Science:

• Pharmaceutical Chemistry
• Drug Stability
• Photochemistry

Background:

• SU5416 is a novel angiogenesis inhibitor.
• The Z-isomer of SU5416 is susceptible to light-induced conversion to the E-isomer.
• Understanding this Z-E isomerism is crucial for pharmaceutical formulation and storage.

Purpose of the Study:

• To investigate the kinetics of Z-E isomerism of SU5416 in pharmaceutical media.
• To determine the impact of light exposure and temperature on SU5416 stability.
• To assess the implications of isomerism for pharmaceutical product quality and patient safety.

Main Methods:

• Kinetic studies of Z-E isomerism in various pharmaceutical media.
• Stability testing of SU5416 under different light and temperature conditions.
• Analysis of isomer content using analytical techniques.

Main Results:

• SU5416 (Z-isomer) converts to the E-isomer upon light exposure and reverts in the dark.
• Light-exposed SU5416 showed a 0.9% increase in E-isomer within 24 hours.
• Light-protected SU5416 remained stable for 18 months at 25°C, with no change in isomer composition.
• Infusate studies predicted less than 1.9% E-isomer administered to patients, likely converting back to Z-isomer.

Conclusions:

• The Z-E isomerism of SU5416 is controllable through appropriate light protection.
• Pharmaceutical product quality and integrity can be maintained with proper storage at 5°C.
• The observed isomerism poses no limitations for ensuring the quality of SU5416 pharmaceutical products.